Company / Current Assets
Viridian Therapeutics, Inc.\DE Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$894.2M
FY2025
5-year range
$200.2M / $894.2M
FY2021-FY2025
Trend
+21.1%
vs FY2024
Sector context
#62 of 213
Health Care
What the data says
At $894M, Viridian Therapeutics, Inc.\DE's current assets ranks #62 of 213 in the Health Care sector. Current Assets has increased for 6 consecutive years, from $30M in FY2019 to $894M in FY2025.
Based on SEC 10-K filings.
$894M in FY2025 with a 5-year CAGR of +47.2%.
Improved from $486M to $894M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +27.5%
- 5-Year CAGR
- +47.2%
- 10-Year CAGR
- -
Sector benchmark
#62 of 213 in Health CareTop 29% of 213This company $894.2M Sector average $2.5B
▼
-64.6% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's current assets has grown for 6 consecutive years.
- 5-year CAGR of +47.2%, indicating consistent growth.
- In FY2025, current assets increased 21.1% year-over-year.
- Ranks #62 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $894.2M | +21.1% |
| FY2024 | $738.5M | +51.8% |
| FY2023 | $486.5M | +12.8% |
| FY2022 | $431.2M | +115.4% |
| FY2021 | $200.2M | +54.4% |
| FY2020 | $129.6M | +335.8% |
| FY2019 | $29.7M | -54.5% |
| FY2018 | $65.4M | +26.0% |
| FY2017 | $51.9M | +117.2% |
| FY2016 | $23.9M | +103.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026